However, the Lung-MAP SWOG S1400G trial (NCT02154490) found that talazoparib (Talzenna) had a lower ORR of 4% in patients with advanced refractory lung squamous cell carcinoma, specifically in tumors with BRCA1/2, ATM, ATR, and PALB2 mutations (Owonikoko et al., 2021). The gene discussed is PALB2; the disease is squamous cell lung carcinoma.